SIGN UP FOR OUR
E-NEWSLETTER
INTERCEPT eNews delivers product news & information updates. 
INTERCEPT Platelets:
A Proven Blood Safety Technology
100,000 units & growing
100,000 INTERCEPT treated platelet concentrates have been transfused to date; the technology has been used clinically in over 40 blood centers located in 13 European countries.
Reductions in transfusion reactions reported
Two blood centers have reported data which indicates a significant reduction in transfusion reactions in routine clinical use at their hospitals.1,2
Release at same time and store up to 7 days
Flexible treatment process does not impact platelet release time and is compatible with up to 7-day storage according to local requirements.
Learn more about INTERCEPT Platelets:
Learn more about the INTERCEPT Blood System:
- A single PI treatment for two components
- Meeting pharmaceutical registraton standards
- INTERCEPT mechanism of action
- Collection and processing information
- News and events
1 JC Osselaer et al., Blood 2005; 106(11):129a.
2 V Witt et al., Vox Sang 2006; 91 (suppl 3):178.
Use of the INTERCEPT Blood System in the United States is limited by Federal law to investigational use. If you are a resident of the U.S., please click here.
The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. The INTERCEPT Blood System is CE marked for use with platelets and plasma.
Website design by NetPilot Web Solutions